LGM
Logos Global Management Portfolio holdings
AUM
$749M
This Quarter Return
+3.52%
1 Year Return
+18.94%
3 Year Return
+431.72%
5 Year Return
+481.1%
10 Year Return
–
AUM
$781M
AUM Growth
+$781M
(+56%)
Cap. Flow
+$283M
Cap. Flow
% of AUM
36.26%
Top 10 Holdings %
Top 10 Hldgs %
66.38%
Holding
71
New
25
Increased
8
Reduced
8
Closed
25
Top Buys
| 1 |
ALX Oncology
ALXO
|
$118M |
| 2 |
Nkarta
NKTX
|
$61.5M |
| 3 |
Keros Therapeutics
KROS
|
$46.3M |
| 4 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$39.4M |
| 5 |
Sarepta Therapeutics
SRPT
|
$38.6M |
Top Sells
| 1 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$31.2M |
| 2 |
BioNTech
BNTX
|
$19.7M |
| 3 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
$16.9M |
| 4 |
AMTI
Applied Molecular Transport Inc. Common Stock
AMTI
|
$16.7M |
| 5 |
Akebia Therapeutics
AKBA
|
$16.3M |
Sector Composition
| 1 | Healthcare | 97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
ALX Oncology
ALXO
$62.7M
| $118M | 15.15% | +3,136,981 | New | +$118M |
|
|
2
Keros Therapeutics
KROS
$618M
| $61.7M | 7.9% | 1,600,000 +1,200,000 | +300% | +$46.3M |
|
|
3
Nkarta
NKTX
$151M
| $61.5M | 7.88% | +2,047,178 | New | +$61.5M |
|
|
FMTX
4
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $58.5M | 7.48% | 1,173,188 -106,812 | -8% | -$5.32M |
|
|
GBT
5
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $46.9M | 6% | 850,000 +715,000 | +530% | +$39.4M |
|
6
TG Therapeutics
TGTX
$4.65B
| $46.8M | 5.99% | 1,750,000 +900,000 | +106% | +$24.1M |
|
|
7
Sarepta Therapeutics
SRPT
$1.78B
| $38.6M | 4.94% | +275,000 | New | +$38.6M |
|
8
Dyne Therapeutics
DYN
$1.92B
| $32.4M | 4.15% | +1,604,392 | New | +$32.4M |
|
9
Repare Therapeutics
RPTX
$71.7M
| $30.1M | 3.85% | 976,894 +310,000 | +46% | +$9.54M |
|
10
BioXcel Therapeutics
BTAI
$59M
| $23.8M | 3.05% | 550,000 +250,000 | +83% | +$10.8M |
|
11
Avidity Biosciences
RNA
$5.99B
| $20.3M | 2.6% | 721,454 -205,000 | -22% | -$5.77M |
|
12
Athira Pharma
ATHA
$15.3M
| $18.8M | 2.41% | +1,020,812 | New | +$18.8M |
|
13
Celldex Therapeutics
CLDX
$1.47B
| $17.8M | 2.28% | 1,200,000 -800,000 | -40% | -$11.9M |
|
|
CMPS
14
Compass Pathways
CMPS
$424M
| $17.5M | 2.23% | +500,000 | New | +$17.5M |
|
15
Cytokinetics
CYTK
$4.23B
| $16.2M | 2.08% | 750,000 -50,000 | -6% | -$1.08M |
|
|
SAGE
16
DELISTED
Sage Therapeutics
SAGE
| $15.3M | 1.96% | +250,000 | New | +$15.3M |
|
|
CALT
17
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
| $13.2M | 1.69% | 550,000 +250,000 | +83% | +$6M |
|
|
BMY.RT
18
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $12.4M | 1.58% | 5,500,000 +1,500,000 | +38% | +$3.38M |
|
19
Kymera Therapeutics
KYMR
$2.95B
| $9.72M | 1.24% | +300,920 | New | +$9.72M |
|
20
Nurix Therapeutics
NRIX
$714M
| $9.6M | 1.23% | +275,000 | New | +$9.6M |
|
21
Harmony Biosciences
HRMY
$2.12B
| $9.32M | 1.19% | +275,000 | New | +$9.32M |
|
22
iTeos Therapeutics
ITOS
| $7.4M | 0.95% | +300,000 | New | +$7.4M |
|
|
PNT
23
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $7.19M | 0.92% | +500,000 | New | +$7.19M |
|
|
AKUS
24
DELISTED
Akouos, Inc. Common Stock
AKUS
| $7.09M | 0.91% | 310,000 -140,000 | -31% | -$3.2M |
|
25
Cogent Biosciences
COGT
$1.69B
| $6.32M | 0.81% | +2,700,000 | New | +$6.32M |
|